Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Sexually Transmitted Diseases|March 5, 2002
Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivityPhilip E Castle, Tammy Shields, Reinhard Kirnbauer, et al.
BMC Research Notes|July 12, 2014
Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyProscovia B Namujju, Emma Pajunen, Aline Simen-Kapeu, et al.
The Journal of General Virology|March 13, 2017
Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in horseEdmund K Hainisch, Hans Abel-Reichwald, Saeed Shafti-Keramat, et al.
BMC Research Notes|June 8, 2011
Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalenceProscovia B Namujju, Lea Hedman, Klaus Hedman, et al.
Journal of Virology|June 15, 2022
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human CancerPola Olczak, Ken Matsui, Margaret Wong, et al.
Cancers|September 28, 2024
BRAF Inhibition and UVB Light Synergistically Promote <i>Mus musculus</i> Papillomavirus 1-Induced Skin TumorigenesisSonja Dorfer, Julia Maria Ressler, Katharina Riebenbauer, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|January 21, 2021
Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccineAlexander Marin, Ananda Chowdhury, Sarah M Valencia, et al.
Vaccine|June 3, 2023
Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse modelChelsea Sanders, Rebecca L Matthews, Sayyed Hamid Zarkesh Esfahani, et al.
Human Vaccines & Immunotherapeutics|February 12, 2021
Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEPSarah M Valencia, Athina Zacharia, Alexander Marin, et al.
Vaccine|December 4, 2024
Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in miceRebecca L Matthews, Nazneen Khan, Bradley Beckman, et al.
Pageof 6